DiaMedica Therapeutics (DMAC) Retained Earnings (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Retained Earnings for 10 consecutive years, with $231.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 26.69% year-over-year to $231.3 million; the trailing twelve-month figure through Jun 2026 stood at $231.3 million (up 26.69% YoY), and the FY2025 full-year result was $228.8 million, up 26.64% from the prior year.
• Retained Earnings rose to $231.3 million in Q2 2026 per DMAC's latest filing, from $230.1 million in the prior quarter.
• Across five years, Retained Earnings topped out at $231.3 million in Q2 2026 and bottomed at $126.9 million in Q1 2022.
• Historically, Retained Earnings has averaged $173.0 million across 5 years, with a median of $173.2 million in 2024.
• The widest YoY moves for Retained Earnings: up 32.61% in 2022, down 1.09% in 2022.
• Over 5 years, Retained Earnings stood at $128.1 million in 2022, then surged by 30.08% to $166.6 million in 2023, then advanced by 8.46% to $180.7 million in 2024, then climbed by 26.64% to $228.8 million in 2025, then grew by 1.09% to $231.3 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $231.3 million, $230.1 million, and $228.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.